evidence-based information about mifepristone, methotrexate & misoprostol

home questions

legal status of abortion worldwide



Vous pouvez aussi lire cette page en français; Puede leer esta pagina in español;  
You can read this page in Arabic
You can read this website in Persian

Who should not use medication abortion?

Most women who have an unwanted pregnancy of nine weeks or less are eligible for medication abortion methods. Medication abortion methods may be contraindicated if a woman suffers from specific conditions or diseases, listed on the table below. Women who have any of these conditions should discuss their eligibility for medication abortion and their abortion care options with a health care provider.

Mifepristone and misoprostol
Methotrexate and misoprostol
Misoprostol alone
  • Confirmed or suspected ectopic pregnancy
  • Allergy to mifepristone
  • Allergy to misoprostol
  • Chronic systemic use of corticosteroids
  • Coagulopathy or current anticoagulant therapy
  • Chronic adrenal failure
  • Inherited porphyries
  • IUD in situ (must be removed prior to use of the medications)
  • Allergy to methotrexate
  • Allergy to misoprostol
  • Coagulopathy
  • Severe anemia
  • Acute or chronic renal disease
  • Acute or chronic hepatic disease
  • Acute inflammatory bowel disease
  • Uncontrolled seizure disorders
  • IUD in situ (must be removed prior to use of the medications)
  • Confirmed or suspected ectopic pregnancy
  • Allergy to misoprostol
  • IUD in situ (must be removed prior to use of the medication)

In addition, women with uterine/genital infections, coagulopathy, hypertension, severe anemia, cardiovascular disease, and/or cerebrovascular disease have been excluded from at least some of the clinical trials.

If you have questions about medication abortion, please visit our frequently asked questions section

Your access and use of this website is subject to certain terms of use. By viewing web pages in this site, you accept, without limitation or qualification, these terms. Read our privacy statement. Last updated January 2015.